← All MEPs

Raphaël Glucksmann

European Parliament · S&D · 🇫🇷 France

Term: since 18 July 2019

Participation in roll-call votes

88 % of the 2,540 roll-call votes held during their term: took part in the vote (for, against or abstention)

Participation month by month

0 % 50 % 100 % July 2019 : participation 100 % (1 / 1), presence 100 % (1 / 1) 2019 September 2019 : participation 100 % (5 / 5), presence 100 % (5 / 5) October 2019 : participation 100 % (19 / 19), presence 100 % (19 / 19) November 2019 : participation 100 % (18 / 18), presence 100 % (18 / 18) December 2019 : participation 100 % (6 / 6), presence 100 % (6 / 6) January 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) 2020 February 2020 : participation 100 % (8 / 8), presence 100 % (8 / 8) May 2020 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) July 2020 : participation 89 % (17 / 19), presence 89 % (17 / 19) September 2020 : participation 100 % (24 / 24), presence 100 % (24 / 24) October 2020 : participation 100 % (37 / 37), presence 100 % (37 / 37) November 2020 : participation 100 % (32 / 32), presence 100 % (32 / 32) December 2020 : participation 97 % (29 / 30), presence 97 % (29 / 30) January 2021 : participation 100 % (23 / 23), presence 100 % (23 / 23) 2021 February 2021 : participation 100 % (21 / 21), presence 100 % (21 / 21) March 2021 : participation 100 % (31 / 31), presence 100 % (31 / 31) April 2021 : participation 99 % (80 / 81), presence 99 % (80 / 81) May 2021 : participation 100 % (26 / 26), presence 100 % (26 / 26) June 2021 : participation 100 % (29 / 29), presence 100 % (29 / 29) July 2021 : participation 100 % (27 / 27), presence 100 % (27 / 27) September 2021 : participation 100 % (19 / 19), presence 100 % (19 / 19) October 2021 : participation 100 % (42 / 42), presence 100 % (42 / 42) November 2021 : participation 100 % (27 / 27), presence 100 % (27 / 27) December 2021 : participation 97 % (28 / 29), presence 97 % (28 / 29) January 2022 : participation 100 % (7 / 7), presence 100 % (7 / 7) 2022 February 2022 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2022 : participation 100 % (37 / 37), presence 100 % (37 / 37) April 2022 : participation 55 % (12 / 22), presence 55 % (12 / 22) May 2022 : participation 99 % (87 / 88), presence 99 % (87 / 88) June 2022 : participation 98 % (45 / 46), presence 98 % (45 / 46) July 2022 : participation 100 % (31 / 31), presence 100 % (31 / 31) September 2022 : participation 100 % (25 / 25), presence 100 % (25 / 25) October 2022 : participation 97 % (31 / 32), presence 97 % (31 / 32) November 2022 : participation 95 % (36 / 38), presence 95 % (36 / 38) December 2022 : participation 89 % (16 / 18), presence 89 % (16 / 18) January 2023 : participation 56 % (9 / 16), presence 56 % (9 / 16) 2023 February 2023 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2023 : participation 21 % (6 / 29), presence 21 % (6 / 29) April 2023 : participation 100 % (24 / 24), presence 100 % (24 / 24) May 2023 : participation 98 % (91 / 93), presence 98 % (91 / 93) June 2023 : participation 100 % (40 / 40), presence 100 % (40 / 40) July 2023 : participation 100 % (40 / 40), presence 100 % (40 / 40) September 2023 : participation 100 % (27 / 27), presence 100 % (27 / 27) October 2023 : participation 75 % (30 / 40), presence 75 % (30 / 40) November 2023 : participation 100 % (53 / 53), presence 100 % (53 / 53) December 2023 : participation 98 % (39 / 40), presence 98 % (39 / 40) January 2024 : participation 98 % (48 / 49), presence 98 % (48 / 49) 2024 February 2024 : participation 98 % (62 / 63), presence 98 % (62 / 63) March 2024 : participation 66 % (33 / 50), presence 66 % (33 / 50) April 2024 : participation 64 % (136 / 213), presence 64 % (136 / 213) July 2024 : participation 100 % (1 / 1), presence 100 % (1 / 1) September 2024 : participation 88 % (7 / 8), presence 88 % (7 / 8) October 2024 : participation 100 % (13 / 13), presence 100 % (13 / 13) November 2024 : participation 96 % (26 / 27), presence 96 % (26 / 27) December 2024 : participation 100 % (18 / 18), presence 100 % (18 / 18) January 2025 : participation 100 % (6 / 6), presence 100 % (6 / 6) 2025 February 2025 : participation 80 % (8 / 10), presence 80 % (8 / 10) March 2025 : participation 79 % (11 / 14), presence 79 % (11 / 14) April 2025 : participation 95 % (21 / 22), presence 95 % (21 / 22) May 2025 : participation 98 % (53 / 54), presence 98 % (53 / 54) June 2025 : participation 100 % (22 / 22), presence 100 % (22 / 22) July 2025 : participation 100 % (32 / 32), presence 100 % (32 / 32) September 2025 : participation 52 % (15 / 29), presence 52 % (15 / 29) October 2025 : participation 78 % (35 / 45), presence 78 % (35 / 45) November 2025 : participation 100 % (51 / 51), presence 100 % (51 / 51) December 2025 : participation 77 % (24 / 31), presence 77 % (24 / 31) January 2026 : participation 86 % (19 / 22), presence 86 % (19 / 22) 2026 February 2026 : participation 100 % (28 / 28), presence 100 % (28 / 28) March 2026 : participation 48 % (21 / 44), presence 48 % (21 / 44) April 2026 : participation 96 % (49 / 51), presence 96 % (49 / 51) May 2026 : participation 96 % (24 / 25), presence 96 % (24 / 25) June 2026 : participation 74 % (26 / 35), presence 74 % (26 / 35) July 2026 : participation 97 % (34 / 35), presence 97 % (34 / 35) September 2026 : participation 90 % (36 / 40), presence 90 % (36 / 40) October 2026 : participation 28 % (15 / 53), presence 28 % (15 / 53) November 2026 : participation 0 % (0 / 13), presence 0 % (0 / 13)

Their votes

2,540 votes

DateTextResultTheir vote
Implementation of the common commercial policy – annual report 2018 Abstention
The Establishment of an EU Mechanism on Democracy, the Rule of Law and Fundamental Rights For
The European Year of Greener Cities 2022 For
COVID-19: EU coordination of health assessments and risk classification, and the consequences for Schengen and the single market For
The cultural recovery of Europe For
The draft Commission regulation amending Annexes II, III and IV to Regulation (EC) No 396/2005 as regards maximum residue levels for cycloxydim, flonicamid, haloxyfop, mandestrobin, mepiquat, Metschnikowia fructicola strain NRRL Y-27328 and prohexadione in or on certain products For
Measures for a sustainable rail market in view of the COVID-19 pandemic For
The humanitarian situation in Mozambique For
The case of Dr. Denis Mukwege in the Democratic Republic of the Congo (DRC) For
The situation in the Philippines, including the case of Maria Ressa For
Resolution on the situation in Russia: the poisoning of Alexei Navalny For
The situation in Belarus For
The preparation of the special European Council summit focusing on the dangerous escalation and the role of Turkey in the Eastern Mediterranean For
Report on the implementation of National Roma Integration Strategies: Combating negative attitudes towards people with Romani background in Europe For
Shortage of medicines - how to address an emerging problem For
Maximising the energy efficiency potential of the EU building stock For
A strategic approach to pharmaceuticals in the environment For
Determination of a clear risk of a serious breach by Poland of the rule of law For
Annual report on arms export For
Just Transition Fund For
Real Driving Emissions  (RDE) For
Annual implementing report on the EU association agreement with Georgia For
Carbon dioxide emissions from maritime transport: global data collection system for ship fuel oil consumption data For
Union Civil Protection Mechanism For
EU-African security cooperation in the Sahel region, West Africa and the Horn of Africa For
The EU’s role in protecting and restoring the world’s forests For
The conclusions of the extraordinary European Council meeting of 17-21 July 2020 For
Conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or pent coronavirus disease For
Emission limits and type-approval for internal combustion engines for non-road mobile machinery: transitional provisions in order to address the impact of COVID-19 crisis For
The revision of the guidelines for trans-European energy infrastructure For
The EU’s public health strategy post-COVID-19 For
A comprehensive Union policy on preventing money laundering and terrorist financing – the Commission’s Action Plan and other recent developments For
The Chemicals Strategy for Sustainability For
European Parliament recommendation to the Council and the Commission concerning the conclusion of an agreement, under negotiation, between the European Union and New Zealand on the exchange of personal data between the European Union Agency for Law Enforcement Cooperation (Europol) and the New Zealand authorities competent for fighting serious crime and terrorism Absent
A comprehensive European approach to energy storage For
The draft Commission implementing regulation amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, dimethomorph, ethephon, etoxazole, famoxadone, fenamiphos, flumioxazine, fluoxastrobin, folpet, formetanate, metribuzin, milbemectin… For
Objection pursuant to Rule 112(2) and (3): Certain uses of chromium trioxide For
Mobilisation of the Contingency Margin in 2020: continuation of humanitarian support to refugees in Turkey For
Amending budget 5/2020: continuation of the support to refugees and host communities in response to the Syria crisis in Jordan, Lebanon and Turkey For
Guidelines for the employment policies of the Member States For

Rows per page: 20 40 100 200 All